Difference between revisions of "Cytarabine liposomal (DepoCyt)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(earliest label" to "(oldest label") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Pyrimidine analog, mimics cytosine. | + | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.shijiebiaopin.net/upload/product/200971300280710.pdf Cytarabine liposomal (DepoCyt) package insert]</ref><ref>[[:File:Cytarabineliposomal.pdf | Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)]]</ref><ref>[http://depocyt.com/ DepoCyt manufacturer's website]</ref> |
<br>Route: IT | <br>Route: IT | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| Line 6: | Line 6: | ||
*"In-line filters must not be used when administering DepoCyt."<ref name="insert"></ref> | *"In-line filters must not be used when administering DepoCyt."<ref name="insert"></ref> | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 14: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.shijiebiaopin.net/upload/product/200971300280710.pdf Cytarabine liposomal (DepoCyt) package insert]<ref name="insert"></ref> | *[http://www.shijiebiaopin.net/upload/product/200971300280710.pdf Cytarabine liposomal (DepoCyt) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1999-04-01: Initial accelerated approval for intrathecal treatment of [[CNS lymphoma|lymphomatous meningitis]]. ''(Based on Glantz et al. 1999)'' |
| − | ** | + | **2007-04-19: Converted to regular approval for intrathecal treatment of [[CNS lymphoma|lymphomatous meningitis]]. |
| − | * | + | *2011-08-11 (oldest label available at Drugs @ FDA): indicated for the intrathecal treatment of [[CNS lymphoma|lymphomatous meningitis]]. |
| − | + | ==History of changes in EMA indication== | |
| + | *2001-07-11: Initial authorization as DepoCyte | ||
| + | *2018-07-10: Withdrawn on request from the manufacturer, for commercial reasons | ||
==Also known as== | ==Also known as== | ||
*'''Generic name:''' Liposomal Ara-C | *'''Generic name:''' Liposomal Ara-C | ||
| − | *'''Brand name:''' DepoCyt | + | *'''Brand name:''' DepoCyt, DepoCyte |
==References== | ==References== | ||
| Line 33: | Line 35: | ||
[[Category:Liposomal chemotherapy]] | [[Category:Liposomal chemotherapy]] | ||
| − | [[Category:Deoxycytidine | + | [[Category:Deoxycytidine analogs]] |
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
| Line 42: | Line 44: | ||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
| + | [[Category:EMA approved in 2001]] | ||
| + | [[Category:EMA withdrawn in 2018]] | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2][3]
Route: IT
Extravasation: irritant
- "In-line filters must not be used when administering DepoCyt."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cytarabine liposomal (DepoCyt) package insert[1]
- Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)[4]
- Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1999-04-01: Initial accelerated approval for intrathecal treatment of lymphomatous meningitis. (Based on Glantz et al. 1999)
- 2007-04-19: Converted to regular approval for intrathecal treatment of lymphomatous meningitis.
- 2011-08-11 (oldest label available at Drugs @ FDA): indicated for the intrathecal treatment of lymphomatous meningitis.
History of changes in EMA indication
- 2001-07-11: Initial authorization as DepoCyte
- 2018-07-10: Withdrawn on request from the manufacturer, for commercial reasons
Also known as
- Generic name: Liposomal Ara-C
- Brand name: DepoCyt, DepoCyte
References
- ↑ 1.0 1.1 1.2 1.3 Cytarabine liposomal (DepoCyt) package insert
- ↑ Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)
- ↑ DepoCyt manufacturer's website
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)